Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information by Popov, Z et al.
Invasive behaviour is a key difference between benign and malig-
nant tumour cells. Acquisition of invasive potential by malignant
cells results from an accumulation of characteristics including
increased cell motility, secretion of proteolytic enzymes, and alter-
ations of cell–substrate and cell–cell adhesion (Liotta et al, 1991).
Bladder cancer shows a variety of biological behaviours, but
acquisition of metastatic capability is the most relevant to clinical
considerations. The initial step in local invasion by malignant
epithelial tumours is cell detachment from the epithelial sheet.
Decreased cell–cell adhesiveness favours detachment of tumour
cells and may play a role in the early steps of the metastatic
process. Although cell–cell adhesion is a complex mechanism
involving at least four families of adhesion molecules (the inte-
grin, immunoglobulin, selectin and cadherin families), several
lines of evidence indicate that E-cadherin-mediated adhesiveness
is crucial for epithelial integrity (Takeichi, 1991). Cadherins are
functionally related transmembrane glycoproteins responsible for
the Ca2+ dependent cell–cell adhesion mechanism that underlies
the mutual association of vertebrate cells. E-cadherin molecules,
which are mainly found in epithelial tissues, contribute to organo-
genesis and morphogenesis (Shimoyama et al, 1989).
The causal relationship between decreased E-cadherin expres-
sion and acquisition of invasive capacity has recently received
strong support: modulation of E-cadherin function in several
tumour cell lines by the use of blocking antibodies or transfection
has revealed an invasion-suppressor role of E-cadherin-mediated
cell–cell adhesion in vitro (Behrens et al, 1989; Frixen et al, 1991;
Vleminckx et al, 1991). These and other experimental observa-
tions suggest that E-cadherin counters tumour spread. E-cadherin
has also been examined in a number of human epithelial tumours,
such as ductal carcinomas of the mammary gland (Shiozaki et al,
1991), prostate carcinomas (Umbas et al, 1992), and bladder carci-
nomas (Bringuier et al, 1993; Lipponen and Eskelinen, 1995; Otto
et al, 1997). In general, E-cadherin is present in differentiated
tumours, whereas expression is lost to variable extents in dediffer-
entiated, aggressively growing tumours of the same cellular origin,
suggesting that the negative relationship between local invasive-
ness and E-cadherin expression also holds for cancer cells in vivo.
There is still a paucity of markers for bladder tumour aggres-
siveness, and identification of the molecular steps associated with
acquisition of metastatic potential would serve as a basis for diag-
nostic methods with predictive value (Raghavan et al, 1990).
Decreased E-cadherin expression in the bladder has been linked to
a loss of differentiation (Frixen et al, 1991; Vleminckx et al, 1991;
Behrens, 1994) and tumour aggressiveness (Takeichi, 1993; Rebel
et al, 1994) but few studies have compared its predictive value
with that of clinical and pathological parameters. Results on the
independent clinical value of E-cadherin immunostaining are
controversial (Bringuier et al, 1993; Lipponen and Eskelinen,
1995; Otto et al, 1997). E-cadherin immunostaining has been
scored arbitrarily as homogenous vs heterogeneous-negative. The
mechanism of E-cadherin down-regulation is not fully understood,
but it is clear that mutation or deletion of the E-cadherin gene is
not the main underlying mechanism in bladder cancer (Knowles et
al, 1994; Giroldi et al, 1994). In addition Giroldi et al, (1999)
suggested that coregulation of the expression of genes encoding
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occurs during tumour progression and that expression of some
catenins is also coordinated with loss of cadherin expression.
To obtain further information on the clinical utility of E-
cadherin expression in bladder cancer, we studied this phenom-
enon at the protein level by means of immunohistochemistry
(IHC) and at the mRNA level by semi-quantitative RT-PCR. The
protein and mRNA expression was compared to histological
parameters for its predictive value as regards to recurrence,
progression and survival. We found a significant prognostic value
of immunohistochemical staining and the level of RT-PCR
transcripts.
MATERIALS AND METHODS
Clinical data
Pathological and clinical data are summarized in Table 1. Patients
included in this study were recruited between October 1987 and
December 1993. They were newly diagnosed cases with a tumour
volume sufficient to allow an immediate frozen aliquot. Tumour
volumes were measured using an endoscopic loop as ruler.
Macroscopic findings from cystoscopies or cystectomies were
reported on a scheme including tumour shape (papillary or solid)
and size. Patients included were those treated with curative intent
by senior urologists as follows: low-risk superficial TCC with
transurethral resection (TUR) and follow-up; high-risk superficial
TCC with TUR and bacille Calmette-Guerin intravesical instilla-
tions. Radical cystectomy was performed for invasive disease
or high-risk superficial TCC for which conservative measures
failed. None of the patients included in this study had received
preoperative radiation or chemotherapy.
Criteria for recurrence and progression were adapted from Herr
et al (1989). Recurrence was defined as occurrence of TCC of any
stage or grade. Progression was defined as death due to TCC or
appearance of distant lymph node or organ metastasis. In case of
tumours initially classified as pT2 or higher, clinical recurrence
after radical cystectomy was considered progression. In case of
tumours initially classified as pTa–pT1, progression was defined
as invasion at least to muscle (pT2) or lesion refractory to TUR
and intravesical therapy, necessitating a change to more radical
treatment (i.e. cystectomy). Disease-specific survival curves were
derived taking death from urothelial carcinoma as end-point.
Immunohistochemistry
Frozen sections (5 mm) from 111 bladder tumours and 13 normal
bladder specimens were fixed with 4% paraformaldehyde and
analysed by using the mouse monoclonal antibody HECD-1
(Takara Biomedical, Kyoto, Japan) against E-cadherin at 7 mg ml–1
dilution and a standard avidin–biotin immunoperoxidase
complexes detection system, as according to the manufacturer’s
protocol (Vectastain Elite ABC kit, Vector Laboratories Inc.,
Burlingame, CA, USA). E-cadherin expression was scored
according to Shiozaki et al, 1991 and Bringuier et al, 1993, who
classified tumours as normal if staining was similar to that of
normal urothelium. Abnormal tumours were defined as those
giving negative (complete absence of immunoreactivity) or
heterogeneous staining (positive and negative areas).
RT-PCR assay
RNA was extracted from five normal bladder specimens and 40
TCCs of the bladder (21 Ta/T1; 19 T2/T4; 9 G1, 15 G2 and 16
G3), according to Chirgwin et al (1979), using 4 M guanidinium
thiocyanate extraction and cesium chloride ultracentrifugation.
The amount of E-cadherin mRNA was determined by semi-quanti-
tative RT-PCR by comparison with an internal control, a ubiqui-
tous transcription factor TBP or GADPH as previously reported
(Gil-Diez de Medina et al, 1997). Twenty-two cycles were used for
the co-amplification of E-cadherin and TBP.
The primers sequences of TBP and GADPH are as described
by Gil-Diez de Medina et al (1997). The primers sequences of
E-cadherin are: GACCAAGTGACCACCTTAGA and GCAGGA-
ATTTGCAATCCTGCT (5¢ to 3¢ direction). After gel electro-
phoresis, the PCR-amplified products were quantified with a
Molecular Dynamics 300 PhosphorImager (Sunnyvale, CA, USA).
Statistical analysis
E-cadherin expression and clinical and pathological parameters
were compared in patients with and without recurrence, progres-
sion or death from TCC. Means of continuous variables were
compared by analysis of variance (multiple groups) and Student’s
t-test (two groups). Frequency distributions were tested by the chi-
squared method. Recurrence and progression-free intervals (in
person-months) were defined from the date of initial staging (and
E-cadherin expression assay) and the date of recurrence or disease
progression. Mean follow-up was 36 months, and ranged from
10–136 months. The expression of the E-cadherin transcript was
quantified in arbitrary units comparing, using a PhosphorImager,
the expression of E-cadherin to the internal control. The cut-off
value of E-cadherin expression for low and high expression was
defined by 30% of the average values found in normal urothelium.
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Table 1 Summary of pathological and clinical data. Characteristics of 111
patients with TCC of the bladder, according to age, sex ratio, histologic type
and grade (WHO classification) of disease, stage (UICC TNM classification),
multifocality, growth pattern and tumour size
Number of patients %
Male 92 82.9
Female 19 17.1
TCC 111 100
Ta 15 13.5
T1 45 40.6
T2 20 18.0
T3 22 19.8
T4 9 8.1
G1 29 26.2
G2 32 28.8
G3 50 45.0
N0 106 95.5
N+ 5 4.5
M0 111 100
No of tumours:
Unifocal 69 62.2
Multifocal 42 37.8
Shape of tumours:
Papillary 67 60.4
Non papillary 44 39.6
Size of tumours in mm, mean (range) 40 (3–90)
Age in years, mean (range) 65 (29–91)The Kaplan–Meier method was used to derive the recurrence,
progression and survival-free functions, while the log-rank test
was used to compare curves with low and high E-cadherin expres-
sion by mean of IHC and RT-PCR. To determine the independent
prognostic value of each variable, stepwise logistic regression was
run using IHC group on BMDP software and odds ratios (OR)
were estimated using the 95% confidence interval (CI). To
compare the power and independence of each prognostic variable,
we ran a multistep logistic regression procedure on BMDP soft-
ware to determine (P) values and odd ratios (OR) in univariate and
multivariate analysis.
RESULTS
The typical pattern of immunostaining for E-Cadherin in normal
urothelium and different bladder carcinomas is shown in Figure 1.
In normal urothelium only the cell–cell borders were stained, as in
other epithelial tissues; the part of the cells in contact with the
basement membrane did not react with the anti-E-cadherin anti-
body (Figure 1A). Fifty tumours (45%) showed a normal staining
pattern (Figure 1B, C, D), while 61 tumours (55%) showed
abnormal E-cadherin expression (Figure 1E, F). Fourteen tumours
(12.61%) were completely negative (Figure 1F). The prevailing
mRNA and protein E-cadherin expression in bladder cancer 211
British Journal of Cancer (2000) 83(2), 209–214 © 2000 Cancer Research Campaign
AB
CD
EF
Figure 1 Representative immunostaining of E-cadherin protein (magnification ´ 400) (A) In normal urothelium only the cell–cell borders are stained; the part of
the cells in contact with the basement membrane does not react with anti-E-cadherin antibody. (B), (C), (D) Similar positive (normal) staining pattern in TaG1,
T3aG3 and T1bG3 bladder tumours. (E) Heterogeneous staining in a T2G3 bladder tumour. Some cells show clear staining at the cell–cell border, whereas
other areas are negative. (F) Negative staining in a T2G3 bladder tumour. Almost all the cells are completely negative.abnormal pattern was heterogeneous (47 specimens, 42.3%). Most
of these specimens contained multiple foci of negative malignant
cells.
Comparison of E-cadherin expression with classical histopatho-
logical features revealed that abnormal E-cadherin expression
detected by immunohistochemistry correlated with both stage and
grade (P < 0.0001 and P < 0.001, respectively Table 2), and with
tumour shape and size (P = 0.0007 and P = 0.0017, respectively)
but not with sex or multiplicity.
Analysis of recurrence, progression and cancer-specific survival
(Figure 2) over a mean of 36 months after surgery in the entire
cohort showed that abnormal E-cadherin immunoreactivity
correlated strongly with poor outcome (log-rank test: P = 0.001,
P < 0.0001 and P = 0.0003, respectively). Recurrence occurred in
67 patients, progression in 48 patients, relation with stage and
grade is described on Table 3. The length of follow-up for
surviving patients was less than 12 months for 14 patients, 12–24
months for 10 patients and more than 24 months for 49 patients.
During the period study 39 patients were dying.
The level of E-cadherin mRNA correlated strongly with stage
and grade, (c2, P = 0.0036 and P = 0.002, respectively) and is also
associated with poor outcome, shown in Figure 3 (P = 0.0006).
In univariate analysis, stage, grade, size, multiplicity and
E-cadherin immunoreactivity were each found to have separate
effects. However, in the final model of multistep logistic regres-
sion only E-cadherin status and stage had significant independent
prognostic value (P = 0.008, OR = 0.2 and P = 0.03, OR = 3.6,
respectively).
DISCUSSION
We analysed the expression of the intercellular adhesion molecule
E-cadherin in sections of normal and malignant human urothe-
lium. In a cohort of 111 patients treated with standard protocols,
E-cadherin expression was associated with tumour recurrence,
progression and survival, and provided information independent
of tumour stage and grade and these results were in agreement
with those of Otto et al (1997).
As E-cadherin is thought to counter tumour invasion, tumours
with only a minor fraction of negative cells should have invasive
potential. Abnormal staining (negative or heterogeneous) was
found in 20/60 (33.3%) of the superficial tumours and in 41/51
(80.4%) of the invasive tumours. This strong correlation with
tumour stage indicates that altered E-cadherin expression effec-
tively plays a role in bladder tumour invasiveness, and concords
with the results of other investigations (Behrens et al, 1989; Frixen
et al, 1991; Vleminckx et al, 1991).
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Table 2 E-cadherin immunoreactivity according to tumour stage and grade
Negative
or
Stage Total number heterogeneous (%) Normal (%) P value
Ta 15 2 (13.3) 13 (86.7)
T1 45 18 (40.0) 27 (60.0)
T2 20 15 (75.0) 5 (25.0)
T3 22 19 (86.4) 3 (13.6)
T4 9 7 (77.8) 2 (22.2) < 0.0001
Grade
G1 29 13 (44.8) 16 (55.2)
G2 32 9 (28.1) 23 (71.9)
G3 50 39 (78.0) 11 (22.0) < 0.001
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Table 3 Recurrence and progression as a function of stage and grade
Total number Recurrence Progression
nn (%) n (%)
Stage
Ta 15 6 (40) 1 (6.7)
T1 45 20 (44.4) 10 (22.2)
T2 20 15 (75.0) 12 (60)
T3 22 17 (77.3) 16 (72.7)
T4 9 9 (100) 9 (100)
Grade
G1 29 13 (44.8) 4 (13.8)
G2 32 16 (50) 10 (31.2)
G3 50 38 (76.0) 34 (68)
Figure 2 Kaplan–Meier disease-specific survival curve according to
E-cadherin immunostaining, E-cadherin positive vs E-cadherin
negative/heterogeneous, P = 0.0003 log-rank test, demonstrating the effect
of abnormal E-cadherin immunoreactivity on the specific survival of TCC of
the bladder.
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Figure 3 Kaplan–Meier disease-specific survival curve according to
E-cadherin mRNA level: high or normal level of E-cadherin mRNA vs low
level of E-cadherin mRNA, P = 0.0006 log-rank test, demonstrating the effect
of low level of E-cadherin mRNA on the specific survival of TCC of the
bladder. E-cadherin mRNA levels were measured by semi-quantitative RT-
PCR.We also found a significant difference in E-cadherin expression
according to the grade of tumour differentiation. Previous studies
(Shimoyama and Hirohashi, 1991; Oka et al, 1993) showed a
correlation between E-cadherin expression and the histological
type of gastric and breast carcinomas. These observations are
consistent with experiments in vitro suggesting that cadherins are
important determinants of tissue morphology. Nagafuchi et al
(1987) showed that forced expression of E-cadherin complemen-
tary DNA in fibroblastic cells generated epithelial structures, and
E-cadherin causes polarized distribution of Na+, K+-ATPase, an
important factor in establishing cell polarity (McNeill et al, 1990).
E-cadherin mRNA levels was found to correlate with adverse clin-
ical outcome (Giroldi et al, 1994; Imao et al, 1999) in accordance
with the correlation of expression between immunohistochemical
staining and RT-PCR as previously reported (Gil-Diez de Medina
et al, 1999). These results suggest that the alteration occurs at the
transcriptional level. In several cases (papillary thyroid, head and
neck, colorectal and bladder cancer), E-cadherin IHC was shown
to be correlated with mRNA expression (Giroldi et al, 1994; Imao
et al, 1999). As no mutations or deletions have been documented
in the E-cadherin gene of bladder tumours (Knowles et al, 1994;
Giroldi et al, 1994), gene silencing by methylation might be
involved as in prostate and breast cancer (Graff et al, 1995).
The immunohistochemical procedure is more practical than
RT- PCR and can be used to assess tumour heterogeneity, which
has prognostic significance. Furthermore, alterations of E-
cadherin expression detected by immunohistochemistry or molec-
ular analysis were strongly associated with grade and stage,
features related to the progression of bladder cancer. These results
are in line with those of Bringuier et al (1993), Lipponen and
Eskelinen (1995), Ross et al (1995), Syrigos et al (1995) and Otto
et al (1997), and indicate that a loss of E-cadherin expression could
be one characteristic of tumour dedifferentiation.
It is striking that most tumours in our series of abnormal
immunostaining (47/61) were not completely negative but were
composed of positive and negative areas. Similar findings have
been reported by Shiozaki et al (1991) in cancers of the oesoph-
agus, stomach and breast, and by Bringuier et al (1993) in bladder
cancer. Heterogeneous E-cadherin expression is likely to reflect
the tumour heterogeneity. Mareel et al (1991) demonstrated that
E-cadherin expression in Madin–Darby canine kidney cells
grown in nude mice was reversibly down-regulated in vivo.
Heterogeneous E-cadherin expression might thus be due not only
to tumour heterogeneity but also to unstable expression in a clone
in vivo.
The E-cadherin present in certain tumours, revealed by
immunocytochemistry, might not be functional. For instance,
certain mutations in the E-cadherin gene or changes in E-cadherin-
associated cytoplasmic proteins, the catenins (Ozawa et al, 1990;
Shimazui et al, 1996; Syrigos et al, 1998), may alter their adhesive
functions.
The cytoplasmic tail of E-cadherin interacts with either b- or
g-catenins which bridge E-cadherin to the cytoskeleton through
a-catenin. In addition, E-cadherin function is dependent on its
anchoring to the cytoskeleton (Shimoyama et al, 1989; Shimazui
et al, 1996). The cytoplasmic immunoreactivity found in several
bladder tumours of our series might be caused by disturbed
E-cadherin-cytoskeleton interactions (Shiozaki et al, 1991;
Bringuier et al, 1993).
Soluble forms of E-cadherin (sE-cadherin) have been detected
in the urine and serum of patients with bladder cancer (Banks et al,
1995; Griffiths et al, 1996). Concentrations of urinary E-cadherin
together with increased E-cadherin amounts in the serum of some
patients with higher-grade invasive tumours suggest that increased
proteolytic activity in tumours may contribute to the release of
the soluble form. In contrast, there was no correlation between
E-cadherin immunostaining and soluble E-cadherin levels,
suggesting two different mechanisms for this observation
(Griffiths et al, 1996).
Tissue cadherin expression is more likely to reflect genetic
abnormalities, as we found a correlation between mRNA levels
and immunohistochemical staining.
Several in vitro and in vivo studies have shown that alteration or
loss of E-cadherin expression is associated with a change in cell
morphology, increased cell migration, and invasion (Frixen et al,
1991; Schipper et al, 1991; Vleminckx et al, 1991). In addition,
positive E-cadherin expression was reported in all specimens of
normal prostate, benign prostatic hyperplasia, and well-differenti-
ated prostatic carcinoma, while expression was reduced in 90% of
poorly differentiated and 93% of locally advanced prostatic carci-
nomas (Otto et al, 1993). It has also been reported that a decrease
in E-cadherin expression correlates with poor survival in patients
with bladder carcinoma (Bringuier et al, 1993; Syrigos et al, 1995;
Otto et al, 1997; Imao et al, 1999).
Our results support the above findings, suggesting that
E-cadherin may play an important role in the genesis of histolog-
ical differentiation and affect the invasive or metastatic behaviour
of bladder cancer cells in vivo. We infer that abnormal E-cadherin
expression is associated with tumour recurrence, progression and
survival, and has prognostic value independently of tumour stage
and grade. While further investigations are required to confirm its
role in cancer metastasis, our results suggest that E-cadherin
expression may be used as a metastatic or prognostic marker in
human bladder cancer.
The main limitation of our study is that the results were obtained
on fresh frozen material. Other investigators have shown that
results obtained with formalin-fixed paraffin-embedded material
are not reliable (Ruijter et al, 1997). Improvement of fixation
procedures in use for others molecules involved in the cell-
cadherin complex, particularly catenins, have been proposed to
study this biological phenomenon (Shimazui et al, 1996).
In conclusion, this study confirms the relevance of cell adhesion
molecule expression to the clinical and biological behaviour of
bladder cancer. This new class of marker, which is independent of
clinical and pathological parameters, should now be compared to
other potential markers, particularly molecules involved in cell-
cycle regulations, such as Rb and p53, or cell proliferation, such as
EGF-R and MIB-1.
ACKNOWLEDGEMENTS
This study was supported in part by Institut Curie, Ligue Nationale
Contre le Cancer, Comité Paris and Comité du Val de Marne
(Créteil), Université Paris XII, Association Claude Bernard,
Association de la Recherche Contre le Cancer, Délégation à la
Recherche Clinique and Assistance Publique Hôpitaux de Paris
AP-HP (PHRC No: AOA94015).
mRNA and protein E-cadherin expression in bladder cancer 213
British Journal of Cancer (2000) 83(2), 209–214 © 2000 Cancer Research CampaignREFERENCES
Banks RE, Porter WH, Whelan P, Smith PH and Selby PJ (1995) Soluble forms of
the adhesion molecule E-cadherin in urine. J Clin Pathol 48: 179–180
Behrens J (1994) Cell contacts, differentiation and invasiveness of epithelial cells.
Invasion Metastasis 14: 61–70
Behrens J, Mareel MM, Van Roy FM and Birchmeier W (1989) Dissecting tumor
cell invasion: epithelial cells acquire invasive properties after the loss of
uvomorulin-mediated cell–cell adhesion. J Cell Biol 108: 2435–2447
Bringuier PP, Umbas R, Schaafsma HE, Karthaus HFM, Debruyne FMJ and
Schalken JA (1993) Decreased E-cadherin immunoreactivity correlates with
poor survival in patients with bladder tumors. Cancer Res 53: 3241–3245
Chirgwin JM, Przybyla AE, Mac Donald RJ and Rutter WJ (1979) Isolation of
biologically active ribonucleic acid from sources enriched in ribonuclease.
Biochemistry 18: 5294–5299
Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Löchner D and
Birchmeier W (1991) E-cadherin-mediated cell–cell adhesion prevents
invasiveness of human carcinoma cells. J Cell Biol 113: 173–185
Gil-Diez de Medina S, Chopin DK, El Marjou A, Delouvée A, La Rochelle WJ,
Hoznek A, Abbou CC, Aaronson SA, Thiery JP and Radvanyi F (1997)
Decreased expression of keratinocyte growth factor receptor in a subset of
human transitional cell bladder carcinomas. Oncogene 14: 323–330
Gil-Diez de Medina S, Popov Z, Chopin DK, Southgate J, Tucker GC, Delouvée A,
Thiery JP and Radvanyi F (1999) Relationship between E-cadherin and
fibroblast growth factor receptor 2b expression in bladder carcinomas.
Oncogene 18: 5722–5726
Giroldi LA, Bringuier PP and Schalken JA (1994) Defective E-cadherin function in
urological cancers: clinical implications and molecular mechanisms. Invasion
Metastasis 14: 71–81
Giroldi LA, Bringuier PP, Shimazui T, Jansen K and Schalken JA (1999) Changes in
cadherin–catenin complexes in the progression of human bladder carcinoma.
Int J Cancer 2: 70–76
Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrad DF, Isaacs WB, Pitha
PM, Davidson NE and Baylin SB (1995) E-cadherin expression is silenced by
DNA hypermethylation in human breast and prostate carcinomas. Cancer Res
55: 5195–5199
Griffiths TR, Brotherick I, Bishop RI, White MD, Mc Kenna DM, Horne CW,
Shenton BK, Neal DE and Mellon JK (1996) Cell adhesion molecules in
bladder cancer: soluble serum E-cadherin correlates with predictors of
recurrence. Br J Cancer 74: 579–584
Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR Jr and Whitmore WF
(1989) Superficial bladder cancer treated with bacillus Calmette–Guerin: a
multivariate analysis of factors affecting tumor progression. J Urol 141: 22–29
Imao T, Koshida K, Endo Y, Uchibayashi T, Sasaki T and Namiki M (1999)
Dominant role of E-cadherin in the progression of bladder cancer. J Urol 161:
692–698
Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME and Law MG (1994)
Allelotype of human bladder cancer. Cancer Res 54: 531–538
Liotta LA, Steeg PS and Stetler-Stevenson WG (1991) Cancer metastasis and
angiogenesis: an imbalance of positive and negative regulation. Cell 64:
327–336
Lipponen PK and Eskelinen MJ (1995) Reduced expression of E-cadherin is related
to invasive disease and frequent recurrence in bladder cancer. J Cancer Res
Clin Oncol 121: 303–308
Mareel MM, Behrens J, Birchmeier W, De Bruyne GK, Vleminckx K, Hoogewijs A,
Fiers WC and Van Roy FM (1991) Down-regulation of E-cadherin expression
in Madin–Darby canine kidney (MDCK) cells inside tumors of nude mice. Int J
Cancer 47: 922–928
McNeill H, Ozawa M, Kemler R and Nelson WJ (1990) Novel function of the cell
adhesion molecule uvomorulin as an inducer of cell surface polarity. Cell 62:
309–316
Nagafuchi A, Shirayoshi Y, Okazaki K, Yasuda K and Takeichi M (1987)
Transformation of cell adhesion properties by exogenously introduced
E-cadherin cDNA. Nature 329: 341–343
Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, Takatsuka Y,
Matsuyoshi N, Hirano S, Takeichi M and Mori T (1993) Expression of E-
cadherin cell adhesion molecules in human breast cancer tissues and its
relationship to metastasis. Cancer Res 53: 1696–1701
Otto T, Rembrink K, Goepel M, Meyer Schwickerath M and Rübben H (1993)
E-cadherin: a marker for differentiation and invasiveness in prostatic
carcinoma. Urol Res 21: 359–362
Otto T, Bex A, Schmidt U, Raz A and Rübben H (1997) Improved prognosis
assessment for patients with bladder carcinoma. J Pathol 150: 
1919–1923
Ozawa M, Ringwald M and Kemler K (1990) Uvomorulin–catenin 
complex formation is regulated by a specific domain in the cytoplasmic 
region of the cell adhesion molecule. Proc Natl Acad Sci USA 87: 
4246–4250
Raghavan D, Shipley WU, Garnick MB, Russell PJ and Richie JP (1990) 
Biology and management of bladder cancer. N Engl J Med 322: 
1129–1138
Rebel JM, Thijssen CD, Vermey M, Delouvée A, Zwarthoff EC and Van Der Kwast
TH (1994) E-cadherin expression determines the mode of replacement of
normal urothelium by human bladder carcinoma cells. Cancer Res 54:
5488–5492
Ross JS, Del Rosario AD, Figge HL, Sheehan C, Fisher H’A and Bui HX (1995)
E-cadherin expression in papillary transitional cell carcinoma of the urinary
bladder. Hum Pathol 26: 940–944
Ruijter ET, Miller GJ, Aalders TW, Van de Kaa CA, Schalken JA, Debruyne FM
and Boon ME (1997) Rapid microwave-stimulated fixation of entire
prostatectomy specimens. Biomed-II MPC Study Group. J Pathol 183:
369–375
Schipper JH, Frixen UH, Behrens J, Unger A, Jahnke K and Birchmeier W (1991)
Ecadherin expression in squamous cell carcinomas of head and neck: inverse
correlation with tumor dedifferentiation and lymph node metastasis. Cancer
Res 51: 6328–6337
Shimazui T, Schalken JA, Giroldi LA, Jansen CF, Akasa H, Koiso, Debruyne FM
and Bringuier PP (1996) Prognostic value of cadherin-associated molecules
(alpha-, beta, and gamma-catenins and p120cas) in bladder tumors. Cancer Res
56: 4154–4158
Shimoyama Y and Hirohashi S (1991) Expression of E-cadherin and P-cadherin in
gastric carcinomas. Cancer Res 51: 2185–2192
Shimoyama Y, Hirohashi S, Hirano S, Noguchi M, Shimosato Y, Takeichi M and
Abe O (1989) Cadherin cell-adhesion molecules in human epithelial tissues
and carcinomas. Cancer Res 49: 2128–2133
Shiozaki H, Tahara H, Oka H, Miyata M, Kobayashi K, Tamura S, Iihara K,
Doki Y, Hirano S, Takeichi M and Mori T (1991) Expression of
immunoreactive E-cadherin adhesion molecules in human cancers. Am J
Pathol 139: 17–23
Syrigos KN, Krausz T, Waxman J, Pandha H, Rowlinson-Busza G, Verne J,
Epenetos AA and Pignatelli M (1995) E-cadherin expression in bladder cancer
using formalin-fixed paraffin-embedded tissues: correlation with
histopathological grade, tumour stage and survival. Int J Cancer 64:
367–370
Syrigos KN, Harrington K, Waxman J, Krausz T and Pignatelli M (1998) Altered
gamma-catenin expression correlates with poor survival in patients with
bladder cancer. J Urol 160: 1889–1893
Takeichi M (1991) Cadherin cell adhesion receptors as a morphogenetic regulator.
Science 251: 1451–1455
Takeichi M (1993) Cadherins in cancer: implications for invasion and metastasis.
Curr Opin Cell Biol 5: 806–811
Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE,
Debruyne FMJ and Isaacs WB (1992) Expression of the cellular adhesion
molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer
Res 52: 5104–5109
Vleminckx K, Vakaet L Jr, Mareel M, Fiers W and Van Roy F (1991) Genetic
manipulation of E-cadherin expression by epithelial tumor cells reveals an
invasion suppressor role. Cell 66: 107–119
214 Z Popov et al
British Journal of Cancer (2000) 83(2), 209–214 © 2000 Cancer Research Campaign